Lexaria Bioscience Corp. Stock Analysis & AI Score
Lexaria Bioscience Corp. (LEXX) has an ST Score of 33.8 (C-), driven by its Financial Strength (A) and held back by its Profitability (F). Analysts rate it Buy with a $1.50 price target (-55.5% downside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Lexaria Bioscience Corp. (LEXX) has an ST Score of 33.8 (C-), driven by its Financial Strength (A) and held back by its Profitability (F). Analysts rate it Buy with a $1.50 price target (-55.5% downside).
- Strongest
- Financial StrengthA
- Weakest
- ProfitabilityF
All factor grades
- Financial StrengthA
- GrowthB-
- ValuationC
- ForecastD+
- MomentumD
- ProfitabilityF
- Piotroski2/9
Contact
LEXX stock: frequently asked questions
What is LEXX's ST Score?
Lexaria Bioscience Corp. (LEXX) has an ST Score of 33.8 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LEXX a buy, hold, or sell?
Analysts rate LEXX a Buy, with a price target of $1.50 (-55.5% vs the current price). Our ST Score grades it C- (33.8/100). The ST Score is a data-driven signal, not a recommendation.
What are LEXX's factor grades?
Valuation C, Profitability F, Financial Strength A, Momentum D, Growth B-, Forecast D+.
What is LEXX's valuation grade?
Lexaria Bioscience Corp. (LEXX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LEXX's growth grade?
Lexaria Bioscience Corp. (LEXX) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LEXX's profitability grade?
Lexaria Bioscience Corp. (LEXX) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LEXX's financial strength grade?
Lexaria Bioscience Corp. (LEXX) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LEXX?
The average analyst price target for Lexaria Bioscience Corp. (LEXX) is $1.50 from 2 analysts, which is -55.5% versus the recent price of $3.37.
What is LEXX's Piotroski score?
Lexaria Bioscience Corp. (LEXX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.